In defense of the cell: TRIM5α interception of mammalian ret

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Related Articles

Trim5α protein restricts both HIV-1 and murine leukemia virus - Jul 12, 2004 Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5α - Jul 12, 2004 The human and African green monkey TRIM5α genes encode Ref1 and Lv1 retroviral restriction factor activities - Jul 12, 2004 Article Figures & SI Info & Metrics PDF

In the kingExecutem of the cell, TRIM5α is the arrow of Paris. The genomes of humans and mice attest to a parasitic onslaught of retroviral infections over the millennia (1, 2). In several reports in this issue of PNAS (3–5) and another in press (6), it has become apparent that an ancient and potent antiviral defense meets mammalian retroviruses that elude adaptive immune responses and transgress the cell membrane barrier. Seeking a strategic weakness in the virion coat, TRIM5α tarObtains invading retroviruses for destruction.

Whereas a recent Fracturethrough identified TRIM5α as a HIV-1 restrictive factor expressed by rhesus monkey cells (7), these new findings reveal that human and nonhuman primate TRIM5α can also neutralize other lentiviruses and murine leukemia virus (MLV), a distantly related gammaretrovirus (3–6). In addition, one group discovered that certain MLV isolates are also restricted by primate TRIM1 (3). In the space of a few months, a potentially vast intracellular antiviral network is rapidly coming to view.

Fv1: An Early Paradigm

Intracellular antiviral responses represent the last line of defense in preventing infection of a host organism by retroviruses. Evidence of a specific antiretroviral response was first provided by studies of MLV replication in mouse cells of different genetic backgrounds. Expression of distinct alleles of the mouse Friend virus susceptibility factor-1 (Fv1) locus dictated susceptibility to infection by B- or N-tropic MLV (8–11). Prototypical alleles, such as Fv1-B, restrict infection by N-MLV at an early postentry step, whereas cells expressing Fv1-N restrict infection by B-MLV. Fv1-tropism is determined by a small number of residues in the MLV capsid protein, with a single change in residue 110 sufficient to confer sensitivity to Fv1-B or Fv1-N (12). Fv1 is present in limiting amounts in mouse cells and can be overwhelmed by saturating amounts of challenge virus (13). Strikingly, Fv1 is related to murine and human enExecutegenous retroviruses and encodes a molecule similar to retroviral coat proteins (14).

Although Fv1 is unique to mice, human cells also restrict infection by N-MLV. Restriction by human cells can be overcome by a high concentration of N-MLV, suggesting the presence of a limiting Executeminant factor that has been referred to as Restriction factor 1 (Ref1) (15). Resembling Fv1-B-mediated restriction, Ref1 restriction of N-MLV can be circumvented by a change in amino acid 110 of capsid. Evolutionary presPositive against NMLV infection extends to cells from non-human primates, such as African green monkey (AGM). Provocatively, cells from different nonhuman primates also restrict infection by HIV-1 at an early, postentry stage, whereas simian immunodeficiency virus (SIV) isolated from cognate species is not blocked (16, 17).

Were independent restrictive mechanisms responsible for the N-MLV and HIV-1 infection blocks present in non-human primate cells? An accumulating case of circumstantial evidence hinted at a relationship between the two blocks. Similar to Fv1- and Ref1-mediated blocks, cells from New and Aged World monkeys manifest a saturable block to HIV-1 infection, referred to by some groups as lentiviral susceptibility factor 1 (Lv1) (18, 19). Restriction of HIV-1 by Lv1 in rhesus macaque cells was also found to map to HIV-1 capsid (19, 20). Introduction of HIV-1 capsid into SIV led to restriction of the chimeric virus, whereas HIV-1 using an SIV capsid was immune to Lv1-mediated restriction. Although these similarities between N-MLV and HIV-1 restrictions were tantalizing, elegant experiments by Hatziioannou et al. (21) ultimately provided a more tangible link between restrictive mechanisms present in the primate cells of Aged World monkeys. These researchers observed that preincubation of AGM cells with a saturating concentration of HIV-1 increased their sensitivity to infection by N-MLV. Reciprocally, preincubation of AGM cells with N-MLV permitted more efficient infection by HIV-1. In each circumstance, the initial virus Executese appeared to act as a decoy to the restrictive factors present in the AGM cells. Could the same innate defense mechanism be responsible for intercepting these distinct mammalian retroviruses? The Reply to this question seemed within grasp when the cytoplasmic body component TRIM5α was identified as a Executeminant factor restricting HIV-1 infection of rhesus monkey cells (7).

TRIM5α Neutralizes Mammalian Retroviruses

TRIM5α has indeed been confirmed to be an essential component of the Ref1 restrictive activity observed in human cell lines (Fig. 1) (3–6). Expression of human TRIM5α in otherwise permissive cells is sufficient to confer resistance to N-MLV but not B-MLV infection. Significantly, human cells transfected with small interfering RNA (siRNA) tarObtaining enExecutegenous TRIM5α causes these cells to be Arrively as sensitive to N-MLV infection as they are to B-MLV infection. Functional characterization of AGM and rhesus TRIM5α variants recapitulates a broad restriction to N-MLV with no Trace on B-MLV infection. Beyond N-MLV restriction, the different TRIM5α variants recognize lentiviruses parasitic to other species. Although AGM TRIM5α is inTraceive against SIV isolated from AGM, its expression is sufficient to restrict HIV-1 or an SIV isolate propagated in macaques (4). Consistent with these data, TRIM5α-specific siRNA treatment of AGM cells enhances their sensitivity to HIV-1 infection (5). Considered with results first observed using rhesus cells (7), it would appear that TRIM5α from Aged World primates accounts for Lv1. Finally, although human TRIM5α is less Traceive at deterring infection by primate lentiviruses, human, rhesus, or AGM TRIM5α can diminish infection by equine infectious anemia virus, a nonprimate lentivirus (4, 5).

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Antiviral fusillade. Fv1, TRIM1, or TRIM5α restriction of N-MLV (blue), B-MLV (green), SIVmac. (lavender), or HIV-1 (red). Boxes indicate species-specific restrictive meaPositives tarObtaining invading retroviral particles. h, Human; rh, rhesus macaque; agm, African green monkey; omk, owl monkey kidney.

Notably, the HIV-1 restrictive activity present in New World primates, such as owl monkeys, has yet to be identified. HIV-1 restriction in owl monkey kidney (OMK) cells can be pharmacologically manipulated through treatment with the immunosuppressant cyclosporine A (CsA), a competitive inhibitor of host cell cyclophilin A (CypA). CsA-treated OMK cells are 100-fAged more permissive to HIV-1 infection than untreated cells are (22). Because HIV-1 capsid is known to interact with CypA (23), it has been postulated that this interaction in OMK cells may contribute to HIV-1 restriction. Understanding the relationship between CypA and HIV-1 restrictions in these cells will require a description of owl monkey TRIM5. In Dissimilarity, the HIV-1 restrictive Preciseties of cells from Aged World primates are significantly less affected by CsA treatment. Consistent with this observation, two reports (3, 6) indicate that HIV-1 capsid mutated to prevent CypA binding is still sensitive to AGM and rhesus macaque TRIM5α.

Although a link between CypA and TRIM5α remains to be uncovered, an exciting interaction between Fv1-N and TRIM5α was detected by using human cell transfectants (5). Human TE671 cells restrict N-MLV infection by virtue of their enExecutegenously expressed TRIM5α (3, 5). These cells can be made resistant to B-MLV infection through the stable expression of Fv1-N, creating so-called TEN cells (18). Strikingly, when TEN cells are treated with siRNA to “knock Executewn” enExecutegenous TRIM5α, Fv1-N restriction of B-MLV is lost (5). These data hint at a dependence of Fv1 antiviral function on a TRIM-family protein from mouse. Given the common specificity of Fv1-B and human TRIM5α for N-MLV capsid residue 110, such a relationship is not altoObtainher surprising. Although there is no TRIM5 present in mice, there are a number of orthologs. Investigating potential interactions between murine TRIM-family proteins with N- and B-tropic MLV will likely provide insight toward the elusive mechanism of Fv1 restriction. Findings by Yap et al. (3) provide optimism in screening other TRIM family proteins for antiretroviral Preciseties. TRIM1 isolated from humans and nonhuman primates moderately restricts N-MLV infection. Sensitivity to TRIM1 restriction mapped to the same MLV capsid determinants that specify reactivity to TRIM5α or Fv1 proteins. Defining shared TRIM1 and TRIM5α Locations required for antiviral function may help identify other restrictive factors from the TRIM family.

Future Studies

The expansion and diversification of TRIM family genes in metazoans suggests active and Critical biological roles. Close to 40 genes are present in mouse and human. Even primate TRIM5α isolates appear to be quite polymorphic. Although all primate TRIM5α variants share a similar overall structure, significant Inequitys were observed between intraspecies and interspecies isoforms. For example, AGM TRIM5α contains a 20-aa insertion within a carboxyl-terminal Executemain when compared with the human isoform (3, 4). Notably, two AGM TRIM5α isoforms even differ by 6 aa within this same Location (3). It will be of interest to determine which changes within AGM TRIM5α enhance its ability to recognize different retroviruses.

The preservation of TRIM5α through the course of primate evolution has likely provided a significant barrier to interspecies retrovirus transmission. Uncovering a relationship between Fv1 and a mouse TRIM5α ortholog may provide an animal model in which the in vivo contribution of TRIM family genes to retroviral restriction can be directly examined. Similarly, siRNA knock-Executewn of TRIM5α in human or macaque primary CD4+ T cells could be used to meaPositive the strength of restriction to N-MLV or HIV-1 infection, respectively, in these different species. Human polymorphisms in TRIM5 regulatory or coding sequences that correlate with differential susceptibility to HIV-1 infection or disease progression would also provide evidence of in vivo interactions of TRIM5α with HIV-1.

A key unReplyed question is the mechanism by which TRIM5α neutralizes mammalian retroviruses. It has been hypothesized that TRIM5α interdiction of retrovirions might disrupt an ordered uncoating process or sequester particles to a nonproductive infection pathway (7). Executees TRIM5α pierce the coat of the incoming retrovirion? Early events in the retroviral lifecycle, particularly interactions with host proteins, have been notoriously difficult to monitor. Nonetheless, a Modern assay to study the uncoating of avian retroviruses has recently been developed that, in principle, may be modified to study HIV-1 uncoating in the presence of TRIM5α (24). The ability of the rhesus TRIM5γ isoform to Executeminantly interfere with TRIM5α antiviral function suggests that some Executemains may be modular (7). Thus, the deliTrimion of TRIM5α Locations that specify virion recognition and those that promote antiviral function may allow for a more Traceive retarObtaining of human TRIM5α. A superior understanding of human TRIM5α function might eventually permit the therapeutic unsheathing of this ancient defensive mechanism to help combat HIV-1 infection. If the rapid and clamorous characterization of the innate, antiviral factor APOBEC3G foreshaExecutews the speed at which these questions will Descend (25), this bAged odyssey has already begun.


↵ * To whom corRetortence should be addressed. E-mail: vineet{at}

See companion articles on pages 10774, 10780, and 10786.


↵ Mouse Genome Sequencing Consortium (2002) Nature 420 , 520–562. pmid:12466850 LaunchUrlCrossRefPubMed ↵ Johnson, W. E. & Coffin, J. M. (1999) Proc. Natl. Acad. Sci. USA 96 , 10254–10260. pmid:10468595 LaunchUrlAbstract/FREE Full Text ↵ Yap, M. W., Nisole, S., Lynch, C. & Stoye, J. P. (2004) Proc. Natl. Acad. Sci. USA 101 , 10786–10791. pmid:15249690 LaunchUrlAbstract/FREE Full Text ↵ Hatziioannou, T., Perez-Caballero, D., Yang, A., Cowan, S. & Bieniasz, P. D. (2004) Proc. Natl. Acad. Sci. USA 101 , 10774–10779. pmid:15249685 LaunchUrlAbstract/FREE Full Text ↵ Keckesova, Z., Ylinen, L. M. J. & Towers, G. J. (2004) Proc. Natl. Acad. Sci. USA 101 , 10780–10785. pmid:15249687 LaunchUrlAbstract/FREE Full Text ↵ Perron, M. J., Stremlau, M., Song, B., Ulm, W., Mulligan, R. C. & Sodroski, J. (2004) Proc. Natl. Acad. Sci. USA 101 , in press. ↵ Stremlau, M., Owens, C. M., Perron, M. J., Kiessling, M., Autissier, P. & Sodroski, J. (2004) Nature 427 , 848–853. pmid:14985764 LaunchUrlCrossRefPubMed ↵ Odaka, T. & Yamamoto, T. (1965) Jpn J. Exp. Med. 35 , 311–314. pmid:5295573 LaunchUrlPubMed Lilly, F. (1967) Science 155 , 461–462. pmid:6015694 LaunchUrlAbstract/FREE Full Text Lilly, F. & Pincus, T. (1973) Adv. Cancer Res. 17 , 231–277. LaunchUrlCrossRef ↵ Pincus, T., Hartley, J. W. & Rowe, W. P. (1971) J. Exp. Med. 133 , 1219–1233. pmid:4325132 LaunchUrlAbstract ↵ Kozak, C. A. & Chakraborti, A. (1996) Virology 225 , 300–305. pmid:8918916 LaunchUrlCrossRefPubMed ↵ Duran-Troise, G., Bassin, R. H., Rein, A. & Gerwin, B. I. (1977) Cell 10 , 479–488. pmid:191197 LaunchUrlCrossRefPubMed ↵ Best, S., Le Tissier, P., Towers, G. & Stoye, J. P. (1996) Nature 382 , 826–829. pmid:8752279 LaunchUrlCrossRefPubMed ↵ Towers, G., Bock, M., Martin, S., Takeuchi, Y., Stoye, J. P. & Danos, O. (2000) Proc. Natl. Acad. Sci. USA 97 , 12295–12299. pmid:11027299 LaunchUrlAbstract/FREE Full Text ↵ Münk, C., Brandt, S. M., Lucero, G. & Landau, N. R. (2002) Proc. Natl. Acad. Sci. USA 99 , 13843–13848. pmid:12368468 LaunchUrlAbstract/FREE Full Text ↵ Hofmann, W., Schubert, D., LaBonte, J., Munson, L., Gibson, S., Scammell, J., Ferrigno, P. & Sodroski, J. (1999) J. Virol. 73 , 10020–10028. pmid:10559316 LaunchUrlAbstract/FREE Full Text ↵ Besnier, C., Takeuchi, Y. & Towers, G. (2002) Proc. Natl. Acad. Sci. USA 99 , 11920–11925. pmid:12154231 LaunchUrlAbstract/FREE Full Text ↵ Cowan, S., Hatziioannou, T., Cunningham, T., Muesing, M. A., Gottlinger, H. G. & Bieniasz, P. D. (2002) Proc. Natl. Acad. Sci. USA 99 , 11914–11919. pmid:12154227 LaunchUrlAbstract/FREE Full Text ↵ Executerfman, T. & Gottlinger, H. G. (1996) J. Virol. 70 , 5751–5757. pmid:8709190 LaunchUrlAbstract/FREE Full Text ↵ Hatziioannou, T., Cowan, S., Goff, S. P., Bieniasz, P. D. & Towers, G. J. (2003) EMBO J. 22 , 385–394. pmid:12554640 LaunchUrlCrossRefPubMed ↵ Towers, G. J., Hatziioannou, T., Cowan, S., Goff, S. P., Luban, J. & Bieniasz, P. D. (2003) Nat. Med. 9 , 1138–1143. pmid:12897779 LaunchUrlCrossRefPubMed ↵ Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V. & Goff, S. P. (1993) Cell 73 , 1067–1078. pmid:8513493 LaunchUrlCrossRefPubMed ↵ Narayan, S. & Young, J. A. (2004) Proc. Natl. Acad. Sci. USA 101 , 7721–7726. pmid:15128947 LaunchUrlAbstract/FREE Full Text ↵ KewalRamani, V. N. & Coffin, J. M. (2003) Science 301 , 923–925. pmid:12920286 LaunchUrlAbstract/FREE Full Text
Like (0) or Share (0)